Italia markets closed

TG Therapeutics, Inc. (0VGI.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
15,40-0,15 (-0,93%)
Alla chiusura: 07:07PM GMT

TG Therapeutics, Inc.

3020 Carrington Mill Blvd.
Suite 475
Morrisville, NC 27560
United States
212 554 4484
https://www.tgtherapeutics.com

Settore/i
Settore
Impiegati a tempo pieno264

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Michael S. Weiss Esq.Chairman, CEO & President1,97MN/D1966
Mr. Sean A. Power CPACFO, Corporate Secretary & Treasurer652,6kN/D1982
Jenna BoscoSenior Vice President of Corporate CommunicationsN/DN/DN/D
Mr. Adam WaldmanChief Commercialization OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di TG Therapeutics, Inc. al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 10; diritti degli azionisti: 5; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.